TSLP

Gene

Also known as: TSLP

Related News

Aclaris Therapeutics Details TSLP/ITK Pipeline with Multiple Clinical Readouts Expected in Late 2026

Apr 28, 2026

Aclaris Therapeutics outlined its TSLP antibody and ITK kinase pipeline at the Guggenheim Biotech Summit, with Phase II AD results for bosakitug due in late 2026 and Phase 1b studies for bispecific ATI-052 underway. The company will also announce Phase 1a results for ATI-052 and lead indication selection for ATI-2138 on April 28, 2026.

AAD 2026 and pipeline updates highlight new atopic dermatitis treatment data

Apr 21, 2026

Atopic dermatitis updates in 2026 included long-term upadacitinib safety, phase 3 amlitelimab and rademikibart data, and 5-year interim dupilumab results in children. A market report also listed multiple emerging therapies in late-stage development.

Amgen Stock Rises on Pipeline Expansion and Strong Q4 Results

Mar 03, 2026

Amgen shares have climbed 35% over six months, trading near $388, as analysts raise price targets following strong fourth-quarter 2025 results and expanding oncology pipeline programs including IMDELLTRA and LUMAKRAS.